PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

Table of Contents

1. Preface

1.1 Related Reports

1.2 Upcoming Reports

1.3 Abbreviations

2. Immuno-Oncology Product Definition and Classification

3. Recent Timeline of Immuno-Oncology Approvals

4. Immune Checkpoint Modulators – Trends in Clinical Trial Development

4.1 Clinical Trial Activity for Checkpoint Modulators Remains Essentially Driven by PD-(L)1 and CTLA-4 Targeting Agents

4.2 Academic Institutions Are Key Drivers for Early Stage Clinical Research, but Patient Recruitment is Highly Dependent on Companies

4.3 Geographic Locations of Trials Assessing Immune Checkpoint Modulators

5. Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators

5.1 Clinical Positioning of Marketed PD-(L)1 Inhibitors

5.2 Commercial Attributes of Marketed PD-(L)1 Checkpoint Modulators

5.3 Dynamic of Clinical Development for Marketed PD-(L)1 Checkpoint Modulators

5.4 Clinical Development Coverage of Marketed PD-(L)1 Checkpoint Modulators in Solid Tumors and Blood Cancers

6. Emergence of New Immune Checkpoint Targets

6.1 Emergence of New Checkpoint Targets in Clinical Development

6.2 Clinical Development Coverage of Emerging Targets in Solid Tumors and Blood Cancers – Matrix Analysis

7. Cellular Immunotherapies in Clinical Development

7.1 Clinical Development of Cellular Immunotherapies

7.2 Clinical Development of Cytotoxic Cellular Immunotherapies

8. Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies

8.1 Development of and Opportunities for CAR Cell Therapies

8.2 Development of CAR Cell Therapies in Blood Cancers

8.3 Development of CAR Cell Therapies in Solid Tumors

9. Cell Vaccines: Steady Development Stimulated by Prior IO Success

9.1 Trends in Clinical Development of Cancer Vaccines

10. T-cell Redirecting Therapies: Comparison Between CAR Cell Therapies and Bispecific T-Cell Engager Antibodies

10.1 Development of CAR Cell Therapies and Bispecific T-Cell Engagers

11. Promising IO-IO Combinations Utilizing Oncolytic Viruses

11.1 Combination Strategies of Oncolytic Viruses with Other IO Agents Create New Clinical Opportunities

12. Appendix

12.1 Inclusion Criteria for IO Products

12.2 Exclusion Criteria for IO Products

12.3 Identification of Immuno-Oncology Products Based on Targets and Molecule Types

12.4 Data Export from the Pharma Intelligence Center

12.5 Primary Research

12.6 Bibliography

12.7 About the Authors

12.8 About GlobalData

12.9 Contact Us

12.10 Disclaimer